Therefore, targeting ICD-related ncRNAs can enhance the immunogenicity of tumor cells, overcome resistance to conventional therapies, and improve the effectiveness of classical immunotherapies such as anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.